EP2297140A4 - Nouveaux composés de 1,2,4-oxadiazole et leurs procédés d'utilisation - Google Patents

Nouveaux composés de 1,2,4-oxadiazole et leurs procédés d'utilisation

Info

Publication number
EP2297140A4
EP2297140A4 EP08770247A EP08770247A EP2297140A4 EP 2297140 A4 EP2297140 A4 EP 2297140A4 EP 08770247 A EP08770247 A EP 08770247A EP 08770247 A EP08770247 A EP 08770247A EP 2297140 A4 EP2297140 A4 EP 2297140A4
Authority
EP
European Patent Office
Prior art keywords
novel
methods
oxadiazole compounds
oxadiazole
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08770247A
Other languages
German (de)
English (en)
Other versions
EP2297140A1 (fr
Inventor
Jianguo Ji
Chih-Hung Lee
Kevin B Sippy
Tao Li
Murali Gopalakrishnan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of EP2297140A1 publication Critical patent/EP2297140A1/fr
Publication of EP2297140A4 publication Critical patent/EP2297140A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP08770247A 2008-06-06 2008-06-06 Nouveaux composés de 1,2,4-oxadiazole et leurs procédés d'utilisation Withdrawn EP2297140A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/066002 WO2009148452A1 (fr) 2008-06-06 2008-06-06 Nouveaux composés de 1,2,4-oxadiazole et leurs procédés d'utilisation

Publications (2)

Publication Number Publication Date
EP2297140A1 EP2297140A1 (fr) 2011-03-23
EP2297140A4 true EP2297140A4 (fr) 2012-05-02

Family

ID=41398367

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08770247A Withdrawn EP2297140A4 (fr) 2008-06-06 2008-06-06 Nouveaux composés de 1,2,4-oxadiazole et leurs procédés d'utilisation

Country Status (6)

Country Link
EP (1) EP2297140A4 (fr)
JP (1) JP2011522818A (fr)
CN (1) CN102089297A (fr)
CA (1) CA2725573A1 (fr)
MX (1) MX2010013399A (fr)
WO (1) WO2009148452A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
WO2010009775A1 (fr) 2007-12-07 2010-01-28 Abbott Gmbh & Co. Kg Dérivés d'oxindole à substitution carbamate et utilisation de ceux-ci pour traiter des maladies dépendant de la vasopressine
JP5701607B2 (ja) 2007-12-07 2015-04-15 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー アミドメチル置換オキシインドール誘導体およびバソプレッシン依存性疾患の治療へのこれらの使用
EP2231644B1 (fr) 2007-12-07 2014-01-15 AbbVie Deutschland GmbH & Co KG Dérivés oxindoliques disubstitués en positions 5 et 6 et leur utilisation pour la préparation d'un medicament pour le traitement de maladies liées à la vasopressine
KR20100097195A (ko) 2007-12-07 2010-09-02 애보트 게엠베하 운트 콤파니 카게 ５－할로겐－치환된 옥스인돌 유도체 및 바소프레신－의존성 질병을 치료하기 위한 이의 용도
EP2435080A2 (fr) 2009-05-29 2012-04-04 Abbott Laboratories Compositions pharmaceutiques utilisées dans le traitement de la douleur
BR112012033402A2 (pt) * 2010-07-02 2017-01-24 Gilead Sciences Inc moduladores de canais de íons conforme os compostos heterocíclicos fundidos
WO2012052412A1 (fr) * 2010-10-22 2012-04-26 Bayer Cropscience Ag Nouveaux composés hétérocycliques utilisés en tant qu'agents pour lutter contre des nuisibles
CA2834164A1 (fr) 2011-05-10 2012-11-15 Gilead Sciences, Inc. Benzoxazinones fusionnees comme modulateurs de canal ionique
TW201837023A (zh) 2011-07-01 2018-10-16 美商基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (fr) 2011-07-01 2018-04-28
WO2013057101A1 (fr) * 2011-10-17 2013-04-25 Bayer Intellectual Property Gmbh Oxadiazolyl-pyridinones et -pyridazinones substituées servant d'inhibiteurs de hif
EP2867230B1 (fr) 2012-07-02 2020-02-12 Monsanto Technology LLC Procédé de préparation de 1,2,4-oxadiazoles 3,5-disubstitués
CN106316885B (zh) * 2015-07-03 2019-02-12 普济生物科技（台州）有限公司 一种3-[5-(2-氟苯基)-1,2,4-噁二唑-3-基]苯甲酸的制备方法
IL271149B2 (en) * 2017-06-14 2024-05-01 Trevena Inc Compounds for modulating s1p1 activity and methods of using the same
RU2671563C1 (ru) * 2017-11-13 2018-11-02 Федеральное государственное бюджетное учреждение науки Южный научный центр Российской академии наук 2-фенил-5-(3,4,5-триэтоксифенил)-1,3,4-оксадиазол с люминесцентной активностью
EP4061352A4 (fr) 2019-11-19 2024-02-28 Trevena, Inc. Composés et procédés de préparation de composés modulateurs de s1p1
IL293340A (en) * 2019-12-02 2022-07-01 Storm Therapeutics Ltd Polyheterocyclic compounds as mettl3 inhibitors
CN111138376A (zh) * 2019-12-24 2020-05-12 中山大学 一种3,5-二取代苯基-1,2,4-噁二唑衍生物及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022901A (en) * 1975-03-05 1977-05-10 E. R. Squibb & Sons, Inc. 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles
US4122257A (en) * 1976-06-04 1978-10-24 Hoechst Aktiengesellschaft Benzofuran-oxadiazole compounds
WO1993013083A1 (fr) * 1991-12-31 1993-07-08 Fujisawa Pharmaceutical Co., Ltd. Derives d'oxadiazole a effet inhibiteur de l'acetylcholinesterase et agoniste muscarinique
US20060019976A1 (en) * 2004-07-22 2006-01-26 Karp Gary M Methods for treating Hepatitis C

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006071184A1 (fr) * 2004-12-28 2006-07-06 Astrazeneca Ab Modulateurs de type arylsulfonamide
KR20080000622A (ko) * 2005-04-26 2008-01-02 뉴로서치 에이/에스 신규한 옥사디아졸 유도체 및 이의 의학적 용도
US20100234349A1 (en) * 2006-09-04 2010-09-16 Olsen Gunnar M Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
US20080167286A1 (en) * 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022901A (en) * 1975-03-05 1977-05-10 E. R. Squibb & Sons, Inc. 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles
US4122257A (en) * 1976-06-04 1978-10-24 Hoechst Aktiengesellschaft Benzofuran-oxadiazole compounds
WO1993013083A1 (fr) * 1991-12-31 1993-07-08 Fujisawa Pharmaceutical Co., Ltd. Derives d'oxadiazole a effet inhibiteur de l'acetylcholinesterase et agoniste muscarinique
US20060019976A1 (en) * 2004-07-22 2006-01-26 Karp Gary M Methods for treating Hepatitis C
WO2006019832A1 (fr) * 2004-07-22 2006-02-23 Ptc Therapeutics, Inc. Thienopyridines utilisees pour traiter l'hepatite c

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KOCEVAR ET AL.: "Ring transformations of some 4-aminopteridine-3-oxides and derivatives", TETRAHEDRON, vol. 39, no. 5, 1982, pages 823 - 829, XP002671613 *
POULAIN R F ET AL: "Parallel synthesis of 1,2,4-oxadiazoles from carboxylic acids using an improved, uronium-based, activation", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 42, no. 8, 1 January 2001 (2001-01-01), pages 1495 - 1498, XP002427070, ISSN: 0040-4039, DOI: 10.1016/S0040-4039(00)02293-0 *
See also references of WO2009148452A1 *
STREET L J ET AL: "SYNTHESIS AND SEROTONERGIC ACTIVITY OF 5-(OXADIAZOLYL)TRYPTAMINES: POTENT AGONISTS FOR 5-HT 1D RECEPTORS", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 36, no. 11, 11 May 1993 (1993-05-11), pages 1529 - 1538, XP002058071, ISSN: 0022-2623, DOI: 10.1021/JM00063A003 *

Also Published As

Publication number Publication date
CN102089297A (zh) 2011-06-08
MX2010013399A (es) 2010-12-21
WO2009148452A1 (fr) 2009-12-10
CA2725573A1 (fr) 2009-12-10
EP2297140A1 (fr) 2011-03-23
JP2011522818A (ja) 2011-08-04

Similar Documents

Publication Publication Date Title
EP2297140A4 (fr) Nouveaux composés de 1,2,4-oxadiazole et leurs procédés d'utilisation
HUS1900009I1 (hu) Új vegyületek és készítmények, továbbá alkalmazási eljárásaik
GB201108374D0 (en) Compositions and methods for the treatment of altered synuclein function
IL209781A0 (en) Novel immunoadjuvant flagellin-based compounds and use thereof
IL208063A0 (en) Novel heterocyclic compounds and uses thereof
IL214614A0 (en) Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof
ZA201104463B (en) Compounds and methods of use
IL254218A0 (en) Pipedrine-bridged compounds of the quinoxaline-converted type and their use
IL213168A0 (en) 1,2,4-oxadiazole derivatives and their therapeutic use
IL207384A0 (en) Oligopeptidic compounds and uses thereof
ZA201104396B (en) "substituted isoidoles as bace inhibitors and their use (new compounds 578)"
IL200387A0 (en) Heterocylic compounds, compositions comprising them and methods of their use
EP2340297A4 (fr) Composition, son procédé de fabrication et son utilisation
PL2242491T3 (pl) Nowatorskie zastosowanie 3,3'-diinodolilometanu
EP2170874A4 (fr) Nouveaux composés et leur utilisation
IL192820A0 (en) Novel compounds and use thereof
GB0809319D0 (en) The treatment of puritus
PL1886669T3 (pl) Preparat o działaniu immunotropowym na bazie fosfoglukanu do leczenia przerostu migdałka gardłowego

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110105

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 471/04 20060101ALI20120321BHEP

Ipc: A61K 31/495 20060101ALI20120321BHEP

Ipc: C07D 487/04 20060101ALI20120321BHEP

Ipc: C07D 413/14 20060101ALI20120321BHEP

Ipc: C07D 271/06 20060101ALI20120321BHEP

Ipc: C07D 413/04 20060101AFI20120321BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20120329

17Q First examination report despatched

Effective date: 20121213

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130424